益气清解方联合免疫抑制治疗高风险IgA肾病的随机对照试验方案
本研究为单中心、前瞻性、双盲随机安慰剂对照试验,计划纳入60例经活检证实的高危IgA肾病患者,比较益气清解方联合免疫抑制与安慰剂联合免疫抑制的疗效与安全性。主要复合终点为3年内eGFR下降40%持续3个月、启动持续肾脏替代治疗或CKD死亡,次要终点包括eGFR年下降斜率及24、36、48周蛋白尿缓解率。
要点
- 益气清解方联合免疫抑制治疗高危IgA肾病,采用双盲随机安慰剂对照设计。
- 主要复合终点为3年内eGFR下降40%持续3个月、启动肾脏替代或CKD死亡。
- 计划样本量60例,治疗期48周,随访至3年。
核心结论
- TCM-WINE研究将评估益气清解方联合免疫抑制治疗高危IgA肾病的疗效与安全性。
研究设计与样本
- 单中心、前瞻性、双盲随机安慰剂对照试验,计划随机分配60例活检证实的IgA肾病患者。
- 试验组为益气清解方联合泼尼松(必要时环磷酰胺),对照组为安慰剂联合泼尼松(必要时环磷酰胺)。
- 两组均接受最优支持治疗,治疗期48周,随访至研究完成(3年)。
关键数值与推荐
- 主要复合终点为3年内首次发生eGFR较基线下降40%持续3个月、启动持续肾脏替代治疗或CKD死亡。
- 次要终点包括eGFR年下降斜率(ml/min per 1.73 m2 per year)及第24、36、48周蛋白尿缓解(蛋白尿<0.5 g/day)。
- 第48周评估症状缓解率和炎症状态。
临床怎么用
- 为高危IgA肾病(大量蛋白尿和肾功能不全)提供潜在的中西医结合治疗选项。
局限性
- 单中心设计,计划样本量60例,可能影响结果外推。
- 原文未报告盲法实施细节或中期分析计划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IgA nephropathy (IgAN) is the most common glomerular disease worldwide. It has a high incidence in Asians and is more likely to progress to end-stage renal disease (ESRD). For high-risk IgAN, which is clinically characterized by massive proteinuria and renal dysfunction, however, there has been no international consensus on treatment options. Compared with other developed countries, IgAN patients in China are often found to have severe kidney function loss at initial diagnosis. Yi-Qi-Qing-Jie formula (YQF; a compound recipe of Chinese medicinal herbs) has shown potential renal protection in our previous clinical studies. To further confirm the efficacy and safety of YQF in the treatment of high-risk IgAN, we have designed a prospective double-blind randomized placebo-controlled trial. METHODS/DESIGN: The TCM-WINE study is a single-center, prospective, double-blind randomized placebo-controlled trial. We plan to randomize 60 participants with biopsy-proven IgAN to a YQF combined group (YQF compound combined with prednisolone, and cyclophosphamide if necessary) or an immunosuppression group (placebo-YQF combined with prednisolone, and cyclophosphamide if necessary). The two groups will enter a 48-week in-trial treatment phase and receive post-trial follow-up until study completion (3 years). All patients will receive optimal supportive care. The primary composite outcome is defined as the first occurrence of a 40% decrease in estimated glomerular filtration rate (eGFR) from the baseline lasting for 3 months, initiating continuous renal replacement treatment, or death due to chronic kidney disease (CKD) during the 3-year study phase. The secondary endpoint events are defined as the mean annual eGFR decline rate (eGFR slope, ml/min per 1.73 m2 per year), which is calculated by the eGFR regression curve for each eligible patient, and proteinuria remission (prescribed as proteinuria < 0.5 g/day) at weeks 24, 36, and 48 during the in-trial phase. The remission rate of symptoms and inflammation status will be evaluated at week 48. Safety monitoring and assessment will be undertaken during the study. DISCUSSION: The TCM-WINE study will evaluate the effects and safety of YQF combined therapy compared with immunosuppression monotherapy on the basis of the optimal supportive treatment in high-risk IgAN. The evidence from this study will provide a novel, effective, and safe Chinese characteristic therapy for high-risk IgAN patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03418779. Registered on 18 June 2018.
引用
- Li S, Li JP. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial. Trials. 2020. PMID: 31907076. doi:10.1186/s13063-019-3989-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。